In summary, we have found that tumor suppressor MIIP promotes EGFR degradation via both the proteasomal and lysosomal pathways, resulting in downregulation of EGFR downstream signaling and ultimately in inhibition of lung cancer cell growth. Here, EGFR is linked to lung carcinoma.